Loading…
Cerus Corporation is projected to rise to $2.79 by 2027, a +30% move from its current price of $2.15. CERS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.07 | $2.15 | $2.23 | +0.01% |
| Aug 4 | $2.04 | $2.15 | $2.27 | +0.02% |
| Aug 5 | $2.01 | $2.15 | $2.30 | +0.02% |
| Aug 6 | $1.99 | $2.15 | $2.32 | +0.03% |
| Aug 7 | $1.98 | $2.15 | $2.34 | +0.04% |
| Aug 8 | $1.96 | $2.15 | $2.36 | +0.05% |
| Aug 9 | $1.95 | $2.15 | $2.38 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.95 | $2.15 | $2.38 | +0.05% |
| Week 2 | $1.87 | $2.15 | $2.48 | +0.11% |
| Week 3 | $1.81 | $2.15 | $2.56 | +0.16% |
| Week 4 | $1.76 | $2.15 | $2.63 | +0.22% |
| Week 5 | $1.72 | $2.16 | $2.70 | +0.27% |
| Week 6 | $1.69 | $2.16 | $2.76 | +0.33% |
| Week 7 | $1.66 | $2.16 | $2.81 | +0.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. It offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
It also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996.
The company was incorporated in 1991 and is headquartered in Concord, California.
Cerus Corporation (CERS) is a healthcare company operating in the biomedical products space. The stock currently trades with a price of $2.87 per share and carries a market capitalization of $575.06M, with a rank of 2865. These fundamentals place the stock among smaller-cap healthcare listings.
The current price sits within a near-term technical setup that includes a 30-day range roughly between $2.42 and $3.41, and an implied near-term trajectory that traders will be watching around key levels.
From a price-trajectory perspective, the stock's 50-day simple moving average is $2.82 and the 200-day simple moving average is $2.20, with a near-term support at $2.47 and resistance at $3.28. The RSI(14) stands at 40, and annualized volatility is around 50, suggesting a historically elevated level of fluctuation but a current technical picture that aligns with a bullish sentiment.
A major floor 35.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 52.6% above — a clean break opens room to run.
A major ceiling 70.1% above — clearing it would confirm fresh momentum.
Key CERS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CERS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.78 | Sell | $2.67 | Sell |
| MA 10 | $2.90 | Sell | $2.82 | Sell |
| MA 20 | $3.03 | Sell | $2.91 | Sell |
| MA 50 | $2.86 | Sell | $2.81 | Sell |
| MA 100 | $2.46 | Sell | $2.60 | Sell |
| MA 200 | $2.23 | Sell | $2.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.42 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -377.33 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -32.39 | Sell |
| Bollinger %B (20,2) | -0.44 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 21.96 | Buy |
| Momentum (10) | -0.98 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 2.65 | Sell |
| ADX (14) | 18.47 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture shows bullish sentiment despite an RSI(14) of 40. The price is trading above both the 50-day simple moving average ($2.82) and the 200-day simple moving average ($2.20), which is consistent with a constructive near-term setup.
Key near-term levels to watch are a support at $2.47 and a resistance at $3.28. The 30-day price range runs from $2.42 to $3.41, indicating a relatively tight but active trading window as market participants evaluate risk and potential upside.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.69 | $2.15 | $2.84 | 0% | Neutral | |
| $2.15 | $2.79 | $3.88 | +30% | Bullish | |
| $2.69 | $3.65 | $5.32 | +70% | Bullish | |
| $3.00 | $4.21 | $6.38 | +96% | Bullish | |
| $3.14 | $4.53 | $7.09 | +111% | Bullish | |
| $3.00 | $4.45 | $7.16 | +107% | Bullish | |
| $3.16 | $4.81 | $7.93 | +124% | Bullish | |
| $3.68 | $5.74 | $9.68 | +167% | Bullish | |
| $4.61 | $7.37 | $12.68 | +243% | Bullish | |
| $5.02 | $8.21 | $14.39 | +282% | Bullish | |
| $6.89 | $12.55 | $23.76 | +484% | Bullish | |
| $9.10 | $20.11 | $42.52 | +835% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.69 | $2.15 | $2.66 | +0.00% |
| September 2026 | $1.77 | $2.12 | $2.63 | -1.38% |
| October 2026 | $1.79 | $2.17 | $2.72 | +2.12% |
| November 2026 | $1.86 | $2.26 | $2.88 | +4.58% |
| December 2026 | $1.80 | $2.21 | $2.84 | -2.46% |
Click any year to see its month-by-month CERS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CERS to range from $1.69 to $2.84 through 2026. The $2.15 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CERS price prediction for 2027 points to an average of $2.79 (low $2.15, high $3.88) — a potential gain of +30% on today's $2.15. Buyers look set to stay in control over this stretch.
In 2028, CERS is projected to trade between $2.69 and $5.32, averaging $3.65 — a potential gain of +70% from today's $2.15. That is up +31% on the projected 2027 average. Momentum favours further upside here.
Cerus Corporation's 2029 outlook centres on $4.21, within a $3.00 to $6.38 range. That is up +15% on the projected 2028 average. That marks a +96% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CERS could reach as high as $7.09, with a base case around $4.53 and support toward $3.14 — roughly +111% from $2.15. Momentum favours further upside here.
Expect CERS to range from $3.00 to $7.16 through 2031. The $4.45 average target implies a +107% move from current prices. That is -2% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The CERS price prediction for 2032 points to an average of $4.81 (low $3.16, high $7.93) — a potential gain of +124% on today's $2.15. Momentum favours further upside here.
In 2033, CERS is projected to trade between $3.68 and $9.68, averaging $5.74 — a potential gain of +167% from today's $2.15. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Cerus Corporation's 2034 outlook centres on $7.37, within a $4.61 to $12.68 range. That is up +28% on the projected 2033 average. That marks a +243% change versus current levels. Momentum favours further upside here.
By 2035, CERS could reach as high as $14.39, with a base case around $8.21 and support toward $5.02 — roughly +282% from $2.15. Buyers look set to stay in control over this stretch.
Expect CERS to range from $6.89 to $23.76 through 2040. The $12.55 average target implies a +484% move from current prices. That is up +53% on the projected 2035 average. Momentum favours further upside here.
The CERS price prediction for 2050 points to an average of $20.11 (low $9.10, high $42.52) — a potential gain of +835% on today's $2.15. Buyers look set to stay in control over this stretch.
Investing $1,000 in CERS today (≈ 465.116279 CERS) could be worth
$9,354.9
+$8,354.9 (+835%) by 2050 · US Dollar
Based on the average projected CERS price of $20.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CERSwould be worth at today's price.
$1,000 invested in CERS on Jul 31, 2025 (≈ 781.250017 CERS) would be worth
$1,679.69
+$679.69 (+68.0%) today · 1.68× · US Dollar
Based on a CERS entry price of $1.28 vs. today's $2.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.93 | $733.79 | -26.6% |
| 1 month ago | $3 | $716.67 | -28.3% |
| 3 months ago | $2.72 | $790.44 | -21.0% |
| 6 months ago | $2.32 | $926.72 | -7.3% |
| 1 year ago | $1.28 | $1,679.69 | +68.0% |
| All time (5.0y) ago | $5.13 | $419.1 | -58.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CERS forecast.
Our base-case forecast reaches $4.30 around 2030.
Implied market cap at $4.30: $866.56M
The multi-year forecast provides a path of meaningful upside across the horizon, with the 2026 average price at $2.87 and an average forecast price climbing through the late 2020s and into 2030s. By 2030 the average is $6.97 with an ROI of 143 and a bullish sentiment. The year-by-year progression remains constructive through 2035 (avg $13.97; ROI 386.6) with continued gains in subsequent years (2032 avg $8.28; ROI 188.4; 2033 avg $10.28; ROI 258.3; 2034 avg $12.61; ROI 339.3; 2035 avg $13.97; ROI 386.6).
The forecast extends into the 2040s and 2050, with 2040 average price $23.71 and ROI 726.1, and 2050 average price $42.91 and ROI 1395.1. These figures indicate substantial long-term upside under the stated scenarios, though they represent estimates rather than guarantees. Uncertainty and downside risk remain inherent in any longer-range projection.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $6.97 with an ROI of 143. The forecast range for 2030 is a minimum of $5.22 and a maximum of $10.04, with sentiment labeled as BULLISH.
The forecast shows a bullish sentiment across multiple years (e.g., 2027 onward) with rising average prices and ROI figures (e.g., 2027 avg $4.05, ROI 41.3; 2040 avg $23.71, ROI 726.1; 2050 avg $42.91, ROI 1395.1). These are estimates and not guarantees, and investment outcomes depend on market conditions and other factors.
Yes. The forecast for 2033 shows an average price of $10.28 with a max of $15.64 and a min of $7.32, indicating the potential to surpass $10 in that year.
For 2026, the average forecast price is $2.87 with a 2026 min of $1.69 and max of $3.80; the 2027 forecast shows an average of $4.05 and a max of $5.35, reflecting a near-term upward trajectory.
The 2040 forecast shows an average price of $23.71 with ROI 726.1, and the 2050 forecast shows an average price of $42.91 with ROI 1395.1, indicating substantial long-term potential according to the provided projections.
Cerus Corporation Community Discussion
0Share your Cerus Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.